Geode Capital Management LLC cut its stake in shares of OraSure Technologies (NASDAQ:OSUR) by 4.1% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 562,168 shares of the medical instruments supplier’s stock after selling 23,914 shares during the period. Geode Capital Management LLC’s holdings in OraSure Technologies were worth $10,602,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds also recently made changes to their positions in OSUR. Sei Investments Co. grew its holdings in shares of OraSure Technologies by 422.4% during the third quarter. Sei Investments Co. now owns 14,925 shares of the medical instruments supplier’s stock worth $336,000 after purchasing an additional 12,068 shares in the last quarter. Rhumbline Advisers grew its holdings in shares of OraSure Technologies by 3.9% during the third quarter. Rhumbline Advisers now owns 110,744 shares of the medical instruments supplier’s stock worth $2,492,000 after purchasing an additional 4,150 shares in the last quarter. Schwab Charles Investment Management Inc. grew its holdings in shares of OraSure Technologies by 16.1% during the third quarter. Schwab Charles Investment Management Inc. now owns 262,429 shares of the medical instruments supplier’s stock worth $5,905,000 after purchasing an additional 36,436 shares in the last quarter. KBC Group NV grew its holdings in shares of OraSure Technologies by 80.5% during the third quarter. KBC Group NV now owns 88,502 shares of the medical instruments supplier’s stock worth $1,991,000 after purchasing an additional 39,469 shares in the last quarter. Finally, OxFORD Asset Management LLP purchased a new position in shares of OraSure Technologies during the third quarter worth about $1,323,000. Hedge funds and other institutional investors own 93.67% of the company’s stock.
OSUR has been the subject of several recent analyst reports. BidaskClub raised OraSure Technologies from a “buy” rating to a “strong-buy” rating in a report on Saturday, January 20th. Zacks Investment Research lowered OraSure Technologies from a “buy” rating to a “hold” rating in a report on Tuesday, February 13th. ValuEngine raised OraSure Technologies from a “hold” rating to a “buy” rating in a report on Friday, March 2nd. Finally, Canaccord Genuity reissued a “buy” rating and set a $24.00 price objective on shares of OraSure Technologies in a report on Friday, February 2nd. Three investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $22.25.
Shares of NASDAQ OSUR opened at $16.72 on Monday. OraSure Technologies has a 12 month low of $12.02 and a 12 month high of $23.01. The stock has a market cap of $1,028.18, a PE ratio of 32.78, a price-to-earnings-growth ratio of 4.95 and a beta of 1.65.
OraSure Technologies (NASDAQ:OSUR) last issued its earnings results on Wednesday, February 7th. The medical instruments supplier reported $0.12 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.11 by $0.01. The business had revenue of $52.00 million during the quarter, compared to analyst estimates of $50.20 million. OraSure Technologies had a return on equity of 13.09% and a net margin of 18.52%. OraSure Technologies’s revenue for the quarter was up 46.5% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.13 earnings per share. research analysts forecast that OraSure Technologies will post 0.27 EPS for the current fiscal year.
In other OraSure Technologies news, EVP Brian Smith sold 20,000 shares of the company’s stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $17.97, for a total value of $359,400.00. Following the completion of the sale, the executive vice president now owns 28,075 shares of the company’s stock, valued at $504,507.75. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Stephen S. Phd Tang sold 23,333 shares of the company’s stock in a transaction that occurred on Thursday, February 15th. The stock was sold at an average price of $17.97, for a total value of $419,294.01. Following the completion of the sale, the director now directly owns 59,749 shares of the company’s stock, valued at approximately $1,073,689.53. The disclosure for this sale can be found here. 6.40% of the stock is owned by corporate insiders.
ILLEGAL ACTIVITY WARNING: This article was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this article on another site, it was illegally copied and reposted in violation of US & international trademark & copyright law. The correct version of this article can be viewed at https://www.dispatchtribunal.com/2018/04/09/geode-capital-management-llc-has-10-60-million-stake-in-orasure-technologies-osur.html.
OraSure Technologies Profile
OraSure Technologies, Inc, together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. It operates in two segments, OSUR and DNAG. The company also offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests.
Want to see what other hedge funds are holding OSUR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for OraSure Technologies (NASDAQ:OSUR).
Receive News & Ratings for OraSure Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies and related companies with MarketBeat.com's FREE daily email newsletter.